Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs

References

• Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386:1672–1682.
   PubMed Web of Science ®Google Scholar
• Vieira RT, Caixeta L, Machado S, et al. Epidemiology of early-onset dementia: a review of the literature. Clin Pract Epidemiol Ment Health. 2013;9:88–95.
   PubMedGoogle Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–2477.
   Google Scholar
• Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–1014.
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Respondek G, Stamelou M, et al. Movement disorder society-endorsed PSP study group clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–864.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496–503.
   Google Scholar
• Capozzo R, Sassi C, Hammer MB, et al. Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy. Alzheimers Dement. 2017;13:858–869.
   PubMed Web of Science ®Google Scholar
• Coyle-Gilchrist IT, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86:1736–1743.
   PubMed Web of Science ®Google Scholar
• Josephs KA. Frontotemporal dementia and related disorders: deciphering the enigma. Ann Neurol. 2008;64:4–14.
   PubMed Web of Science ®Google Scholar
• Josephs KA, Hodges JR, Snowden JS, et al. Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathol. 2011;122:137–153.
   PubMed Web of Science ®Google Scholar
• Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5‘-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–705.
   PubMed Web of Science ®Google Scholar
• Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130–133.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205–1208.
   PubMed Web of Science ®Google Scholar
• Bronner IF, Ter Meulen BC, Azmani A, et al. Hereditary Pick‘s disease with the G272V tau mutation shows predominant three-repeat tau pathology. Brain. 2005;128:2645–2653.
   PubMed Web of Science ®Google Scholar
• Chambers CB, Lee JM, Troncoso JC, et al. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer‘s disease. Ann Neurol. 1999;46:325–332.
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Bird TD, Ghetti B. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol. 1998;8:387–402.
   PubMed Web of Science ®Google Scholar
• Togo T, Sahara N, Sh Y, et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol. 2002;61:547–556.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Baborie A, Pickering-Brown S, et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol. 2006;112:539–549.
   PubMed Web of Science ®Google Scholar
• Sampathu DM, Neumann M, Kwong LK, et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol. 2006;169:1343–1352.
   PubMed Web of Science ®Google Scholar
• Cairns NJ, Grossman M, Arnold SE, et al. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology. 2004;63:1376–1384.
   PubMed Web of Science ®Google Scholar
• Kusaka H, Matsumoto S. Imai T An adult-onset case of sporadic motor neuron disease with basophilic inclusions. Acta Neuropathol. 1990;80:660–665.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Foti D, Woulfe J, et al. Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain. 2008;131:1282–1293.
   PubMed Web of Science ®Google Scholar
• Urwin H, Josephs KA, Rohrer JD, et al. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 2010;120:33–41.
   PubMed Web of Science ®Google Scholar
• Rohrer JD, Guerreiro R, Vandrovcova J, et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73:1451–1456.
   PubMed Web of Science ®Google Scholar
• Le Ber I. Genetics of frontotemporal lobar degeneration: an up-date and diagnosis algorithm. Rev Neurol. 2013;169:811–819.
   PubMedGoogle Scholar
• DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–256.
   PubMed Web of Science ®Google Scholar
• Mackenzie IR, Baker M, Pickering-Brown S, et al. The neuropathology of frontotemporallobar degeneration caused by mutations in the progranulin gene. Brain. 2006;129:3081–3090.
   PubMed Web of Science ®Google Scholar
• Masellis M, Momeni P, Meschino W, et al. Novel splicing mutation in the progranulingene causing familial corticobasal syndrome. Brain. 2006;129:3115–3123.
   PubMed Web of Science ®Google Scholar
• Moreno F, Indakoetxea B, Barandiaran M, et al. “Frontotemporoparietal” dementia: clinicalphenotype associated with the c.709–1G>A PGRN mutation. Neurology. 2009;73:1367–1374.
   PubMed Web of Science ®Google Scholar
• Ghetti B, Hutton M, Wszolek Z. Frontotemporal dementia and parkinsonism linked to chromosome 17 associated with tau gene mutations (FTDP-17t). In: Dickson D, editor. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel: ISN Neuropath Press; 2003. p. 86–102.
   Google Scholar
• Pickering-Brown SM, Richardson AM, Snowden JS, et al. Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. Brain. 2002;125:732–751.
   PubMed Web of Science ®Google Scholar
• Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36:377–381.
   PubMed Web of Science ®Google Scholar
• Skibinski G, Parkinson NJ, Brown JM, et al. Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet. 2005;37:806–808.
   PubMed Web of Science ®Google Scholar
• Benajiba L, Le Ber I, Camuzat A, et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol. 2009;65:470–473.
   PubMed Web of Science ®Google Scholar
• Yan J, Deng HX, Siddique N, et al. Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology. 2010;75:807–814.
   PubMed Web of Science ®Google Scholar
• Synofzik M, Maetzler W, Grehl T, et al. Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. Neurobiol Aging. 2012;33:2949e13–7.
   Web of Science ®Google Scholar
• Williams KL, Topp S, Yang S, et al. CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat Commun. 2016;15:11253.
   Web of Science ®Google Scholar
• Lattante S, Rouleau GA, Kabashi E. TARDBP and FUS mutations associated with amyotrophiclateral sclerosis: summary and update. Hum Mutat. 2013;34:812–826.
   PubMed Web of Science ®Google Scholar
• Gao FB, Almeida S, Lopez-Gonzalez R. Dysregulated molecular pathways in amyotrophic lateral sclerosis-frontotemporal dementia spectrum disorder. Embo J. 2017;36:2931–2950.
   PubMed Web of Science ®Google Scholar
• Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19:983–997.
   PubMed Web of Science ®Google Scholar
• Menzies FM, Fleming A, Caricasole A, et al. Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron. 2017;93:1015–1034.
   PubMed Web of Science ®Google Scholar
• Guo Q, Lehmer C, Martínez-Sánchez A, et al. In situ structure of neuronal C9orf72 Poly-GA aggregates reveals proteasome recruitment. Cell. 2018;172:696–705.e12.
   PubMed Web of Science ®Google Scholar
• Janssens J. Van Broeckhoven C Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum Mol Genet. 2013;22:R77–87.
   PubMed Web of Science ®Google Scholar
• Kortvelyessy P, Heinze HJ, Prudlo J, et al. CSF biomarkers of neurodegeneration in progressive non-fluent aphasia and other forms of frontotemporal dementia: clues for pathomechanisms? Front Neurol. 2018;9:504.
   PubMed Web of Science ®Google Scholar
• Zerr I, Schmitz M, Karch A, et al. Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. Alzheimers Dement. 2018;14:751–763.
   PubMed Web of Science ®Google Scholar
• Meeter LHH, Vijverberg EG, Del Campo M, et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018;90:e1231–e1239.
   PubMed Web of Science ®Google Scholar
• Hu WT, Watts K, Grossman M, et al. Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. Neurology. 2013;81:1945–1952.
   PubMed Web of Science ®Google Scholar
• Foiani MS, Woollacott IO, Heller C, et al. Plasma tau is increased in frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2018;89:804–807.
   PubMed Web of Science ®Google Scholar
• Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem. 2016;138(Suppl 1):211–221.
   PubMed Web of Science ®Google Scholar
• Young JJ, Lavakumar M, Tampi D, et al. Frontotemporal dementia: latest evidence and clinical implications. Ther Adv Psychopharmacol. 2018;8:33–48.
   PubMed Web of Science ®Google Scholar
• Ihl R, Frölich L, Winblad B, et al. WFSBP task force on treatment guidelines for alzheimer‘s disease and other dementias world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer‘s disease and other dementias. World J Biol Psychiatry. 2011;12:2–32.
   PubMed Web of Science ®Google Scholar
• Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17–22.
   PubMed Web of Science ®Google Scholar
• Li Y, Hai S, Zhou Y, et al. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev. 2015 Mar 3;(3):CD009444.
   PubMed Web of Science ®Google Scholar
• Buoli M, Serati M, Caldiroli A, et al. Pharmacological management of psychiatric symptoms in frontotemporal dementia: A systematic review. J Geriatr Psychiatry Neurol. 2017;30:162–169.
   PubMed Web of Science ®Google Scholar
• O’Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017;31:147–166.
   PubMed Web of Science ®Google Scholar
• Tsai RM, Boxer AL. Treatment of frontotemporal dementia. Curr Treat Options Neurol. 2014;16:319.
   PubMed Web of Science ®Google Scholar
• Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. Brain. 2018;141:1263–1285.
   PubMed Web of Science ®Google Scholar
• Hoyer D, Palacios JM, Mengod G. 5-HT receptor distribution in the human brain: autoradiographic studies. In: Marsden CA, Heal DJ, editors. Central Serotonin Receptors and Psychotropic Drugs. London: Blackwell Scientific Publications; 1992. p. 100–125.
   Google Scholar
• Wood PL, Etienne P, Lal S, et al. A post-mortem comparison of the cortical cholinergic system in Alzheimer’s disease and Pick’s disease. J Neurol Sci. 1983;62:211–217.
   PubMed Web of Science ®Google Scholar
• Sparks DL, Markesbery WR. Altered serotoninergic and cholinergic synaptic markers Pick’s disease. Arch Neurol. 1991;48:796–799.
   PubMedGoogle Scholar
• Francis PT, Holmes C, Webster MT, et al. Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy. Dementia. 1993;4:72–79.
   Google Scholar
• Miller BL, Darby A, Swartz JR, et al. Dietary changes, compulsions and sexual behaviour in fronto-temporal degeneration. Dementia. 1995;6:195–199.
   PubMedGoogle Scholar
• Miller BL, Ponton M, Benson DF, et al. Enhanced artistic creativity withtemporal lobe degeneration. Lancet. 1996;348:1744–1755.
   PubMed Web of Science ®Google Scholar
• Miller BL, Cummings JL, Boone K, et al. Emergence of artistic talent in frontotemporal dementia. Neurology. 1998;51:978–981.
   PubMed Web of Science ®Google Scholar
• Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatr. 2007;15:84–87.
   PubMed Web of Science ®Google Scholar
• Chow TW. Treatment approaches to symptoms associated with frontotemporal degeneration. Curr Psychiatry Rep. 2005;7:376–380.
   PubMedGoogle Scholar
• Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:931–937.
   PubMed Web of Science ®Google Scholar
• Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178–185.
   PubMed Web of Science ®Google Scholar
• Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57:467–473.
   PubMed Web of Science ®Google Scholar
• Kishi T, Matsunaga S, Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat. 2015;11:2883–2885.
   PubMed Web of Science ®Google Scholar
• Vercelletto M, Boutoleau-Bretonnière C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimer Dis. 2011;23:749–759.
   PubMed Web of Science ®Google Scholar
• Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicenter, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:149–156.
   PubMed Web of Science ®Google Scholar
• Lozupone M, La Montagna M, D‘Urso F, et al. Pharmacotherapy for the treatment of depression in patients with Alzheimer’s disease: a treatment-resistant depressive disorder. Expert Opin Pharmacother. 2018;19:823–842.
   PubMed Web of Science ®Google Scholar
• Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58:212–216.
   PubMed Web of Science ®Google Scholar
• Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2002;17:267–272.
   PubMedGoogle Scholar
• Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. Eur Neurol. 2003;49:13–19.
   PubMed Web of Science ®Google Scholar
• Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004;172:400–408.
   PubMed Web of Science ®Google Scholar
• Herrmann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry. 2012;20:789–797.
   PubMed Web of Science ®Google Scholar
• Hughes LE, Rittman T, Regenthal R, et al. Improving response inhibition systems in frontotemporal dementia with citalopram. Brain. 2015;138:1961–1975.
   PubMed Web of Science ®Google Scholar
• Lebert F, Stekke W, Hasenbroeky C, et al. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355–359.
   PubMed Web of Science ®Google Scholar
• Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005;20:742–745.
   PubMed Web of Science ®Google Scholar
• Prodan CI, Monnon M, Ross ED. Behavioral abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. J Neurol Neurosurg Psychiatry. 2009;80:1416–1417.
   PubMed Web of Science ®Google Scholar
• Anneser JM, Jox RJ, Borasio GD. Inappropriate sexual behavior in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler. 2007;8:189–190.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Shigenobu K, Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord. 2004;17:117–121.
   PubMed Web of Science ®Google Scholar
• Anderson IM, Scott K, Harborne G. Serotonine and depression in frontal lobe dementia. Am J Psychiatry. 1995;152:645.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Progresses in treating agitation: a major clinical challenge in Alzheimer‘s disease. Expert Opin Pharmacother. 2015;16:2581–2588.
   PubMed Web of Science ®Google Scholar
• Pijnenburg YA, Sampson EL, Harvey RJ, et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatr. 2003;18:67–72.
   PubMed Web of Science ®Google Scholar
• Curtis RC, Resch DS. Case of Pick´s central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol. 2000;20:384–385.
   PubMed Web of Science ®Google Scholar
• Fellgiebel A, Müller MJ, Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007;8:123–126.
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205–214.
   PubMedGoogle Scholar
• Jha MK, Lambert ES, Beadles BA, et al. A case of frontotemporal dementia presenting with treatment-refractory psychosis and extreme violence: response to combination of clozapine, medroxyprogesterone, and sertraline. J Clin Psychopharmacol. 2015;35:732.
   PubMed Web of Science ®Google Scholar
• Riedl L, Mackenzie IR, Forstl H, et al. Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr Dis Treat. 2014;10:297–310.
   PubMed Web of Science ®Google Scholar
• Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathotogical correlates in frontotemporal dementia. Ann Neurol. 2004;56:399–406.
   PubMed Web of Science ®Google Scholar
• Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents, council on scientific affairs, American medical association. JAMA. 1998;279:1100–1107.
   PubMed Web of Science ®Google Scholar
• Mega MS, Cummings JL. Frontalsubcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 1994;6:358–370.
   PubMed Web of Science ®Google Scholar
• Huey ED, Garcia C, Wassermann EM, et al. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry. 2008;69:1981–1982.
   PubMed Web of Science ®Google Scholar
• Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate (‘Ritalin’) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31:651–658.
   PubMed Web of Science ®Google Scholar
• Reed DA, Johnson NA, Thompson C, et al. A clinical trial of bromocriptine for treatment of primary progressive aphasia. Ann Neurol. 2004;56:750.
   PubMed Web of Science ®Google Scholar
• Alafuzoff I, Helishami S, Heinonen EH, et al. Selegiline treatment and extent of degenerative changes in brain tissue of patients with Alzheimer’s disease. Eur J Clin Pharmacol. 2000;55:815–819.
   PubMed Web of Science ®Google Scholar
• Adler G, Teufel M, Drach LM. Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry. 2003;18:653–655.
   PubMed Web of Science ®Google Scholar
• Moretti R, Torre P, Antonello RM, et al. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. Int J Geriatr Psychiatry. 2002;17:391–392.
   PubMed Web of Science ®Google Scholar
• Jesso S, Morlog D, Ross S, et al. The effects of oxytocin on social cognition and behavior in frontotemporal dementia. Brain. 2011;134:2493–2501.
   PubMed Web of Science ®Google Scholar
• Finger EC, MacKinley J, Blair M, et al. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. Neurology. 2015;84:174–181.
   PubMed Web of Science ®Google Scholar
• Callegari I, Mattei C, Benassi F, et al. Agomelatine improves apathy in frontotemporal dementia. Neurodegener Dis. 2016;16:352–356.
   PubMed Web of Science ®Google Scholar
• D‘Alton S, Lewis J. Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci. 2014;6:204.
   PubMed Web of Science ®Google Scholar
• De Conti L, Borroni B, Baralle M. New routes in frontotemporal dementia drug discovery. Expert Opin Drug Discov. 2017;12:659–671.
   PubMed Web of Science ®Google Scholar
• Drechsel DN, Hyman AA, Cobb MH, et al. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992;3:1141–1154.
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Jakes R, et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989;3:519–526.
   PubMed Web of Science ®Google Scholar
• Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene. Biochemistry. 1992;3:10626–10633.
   Google Scholar
• Kuret J, Chirita CN, Congdon EE, et al. Pathways of tau fibrillization. Biochim Biophys Acta. 2005;1739:167–178.
   PubMed Web of Science ®Google Scholar
• Holmes BB, Diamond MI. Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. J Biol Chem. 2014;18:19855–19861.
   Web of Science ®Google Scholar
• Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick’s disease and corticobasal degeneration. J Neuropathol Exp Neurol. 1996;55:53–67.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Weidenheim KM, Dickson DW, et al. Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. J Neuropathol Exp Neurol. 2002;61:33–45.
   PubMed Web of Science ®Google Scholar
• Zhukareva V, Mann D, Pickering-Brown S, et al. Sporadic Pick’s disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol. 2002;51:730–739.
   PubMed Web of Science ®Google Scholar
• Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol. 2011;24:542–549.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Tau-Centric targets and drugs in clinical development for the treatment of Alzheimer‘s disease. Biomed Res Int. 2016;2016:3245935.
   PubMed Web of Science ®Google Scholar
• Papazacharias A, Lozupone M, Barulli MR, et al. Bipolar disorder and frontotemporal dementia: an intriguing association. J Alzheimers Dis. 2017;55(3):973–979.
   PubMed Web of Science ®Google Scholar
• Hong M, Chen DC, Klein PS, et al. Lithium reduces tau phosphorylationby inhibition of glycogen synthase kinase-3. J Biol Chem. 1997;272:25326–25332.
   PubMed Web of Science ®Google Scholar
• Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102:6990–6995.
   PubMed Web of Science ®Google Scholar
• Engel T, Goni-Oliver P, Lucas JJ, et al. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem. 2006;99:1445–1555.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29:470–478.
   PubMed Web of Science ®Google Scholar
• van Swieten JC, Heutink P. Mutations in progranulin (GRN) within the spectrum of clinical and pathological phenotypes of frontotemporal dementia. Lancet Neurol. 2008;7:965–974.
   PubMed Web of Science ®Google Scholar
• Ghidoni R, Benussi L, Glionna M, et al. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology. 2008;14:1235–1239.
   Google Scholar
• Boyd JD, Lee-Armandt JP, Feiler MS, et al. A high-content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J Biomol Screen. 2014;19:44–56.
   PubMedGoogle Scholar
• Jiang J, Cleveland DW. Bidirectional transcriptional inhibition as therapy for ALS/FTD caused by repeat expansion in C9orf72. Neuron. 2016;92:1160–1163.
   PubMed Web of Science ®Google Scholar
• Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435–442.
   PubMed Web of Science ®Google Scholar
• Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415–428.
   PubMed Web of Science ®Google Scholar
• Sareen D, O’Rourke JG, Meera P, et al. Targeting RNA foci in iPSC derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. 2013;5:208ra149.
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C, Baughn M, Rigo F, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA. 2013;19:E4530–E4539.
   Google Scholar
• Neumann M, Rademakers R, Roeber S, et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132:2922–2931.
   PubMed Web of Science ®Google Scholar
• Fujii S, Takanashi K, Kitajo K, et al. Treatment with a global methyltransferase inhibitor induces the intranuclear aggregation of ALS-linked FUS mutant in vitro. Neurochem Res. 2016;41:826–835.
   PubMed Web of Science ®Google Scholar
• Wischik CM, P C E, Lai RY, et al. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA. 1996;93:11213–11218.
   PubMed Web of Science ®Google Scholar
• Seripa D, Solfrizzi V, Imbimbo BP, et al. Tau-directed approaches for the treatment of Alzheimer‘s disease: focus on leuco-methylthioninium. Expert Rev Neurother. 2016;16:259–277.
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer‘s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388:2873–2884.
   PubMed Web of Science ®Google Scholar
• TauRx Pharmaceuticals, Press Release, Sep 4. 10th International Conference on Frontotemporal Dementias; 2016; August 31-September 2, 2016; Munich.
   Google Scholar
• Min SW, Chen X, Tracy TE, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2015;21:1154–1162.
   PubMed Web of Science ®Google Scholar
• Lagraoui M, Sukumar G, Latoche JR, et al. Salsalate treatment following traumatic brain injury reduces inflammation and promotes a neuroprotective and neurogenic transcriptional response with concomitant functional recovery. Brain Behav Immun. 2017;61:96–109.
   PubMed Web of Science ®Google Scholar
• Paholikova K, Salingova B, Opattova A, et al. N-terminal truncation of microtubule associated protein tau dysregulates its cellular localization. J Alzheimers Dis. 2015;43:915–926.
   PubMed Web of Science ®Google Scholar
• Kontsekova E, Zilka N, Kovacech B, et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. Alzheimers Res Ther. 2014;6:44.
   PubMed Web of Science ®Google Scholar
• Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer‘s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16:123–134.
   PubMed Web of Science ®Google Scholar
• Panza F, Logroscino G. Anti-tau vaccine in Alzheimer‘s disease: a tentative step. Lancet Neurol. 2017;16:99–100.
   PubMed Web of Science ®Google Scholar
• Novak P, Schmidt R, Kontsekova E, et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer‘s disease. Alzheimers Res Ther. 2018;10:108.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Tau-based therapeutics for Alzheimer‘s disease: active and passive immunotherapy. Immunotherapy. 2016;8:1119–1134.
   PubMed Web of Science ®Google Scholar
• Bright J, Hussain S, Dang V, et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging. 2015;36:693–709.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 2011;121:589–595.
   PubMed Web of Science ®Google Scholar
• Dai CL, Chen X, Kazim SF, et al. Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J Neural Transm (Vienna). 2015;122:607–617.
   PubMed Web of Science ®Google Scholar
• Jarskog LF, Dong Z, Kangarlu A, et al. Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. Neuropsychopharmacology. 2013;38:1245–1252.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Buchanan RW, Keefe RS, et al. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Schizophr Res. 2012;136:25–31.
   PubMed Web of Science ®Google Scholar
• Vulih-Shultzman I, Pinhasov A, Mandel S, et al. al.Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther. 2007;323:438–449.
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Jouroukhin Y, Gray AJ, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease. J Pharmacol Exp Ther. 2008;325:146–153.
   PubMed Web of Science ®Google Scholar
• Jouroukhin Y, Ostritsky R, Assaf Y, et al. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis. 2013;56:79–94.
   PubMed Web of Science ®Google Scholar
• Morimoto BH, Schmechel D, Hirman J, et al. A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment. Dement Geriatr Cogn Disord. 2013;35:325–326.
   PubMed Web of Science ®Google Scholar
• Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13:676–685.
   PubMed Web of Science ®Google Scholar
• Cenik B, Sephton CF, Dewey CM, et al. Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem. 2011;286:16101–16108.
   PubMed Web of Science ®Google Scholar
• Patzke H, Albayya FP, Besterman JM, et al. Development of the novel histone deacetylase inhibitor EVP-0334 for CNS indications. 38th Annual Meeting for the Society of Neuroscience; 2008; Nov 19; Washington DC. Poster 831.21/I12.
   Google Scholar
• Leventhal L, Tran A, Gallager I, et al. The histone deacetylase inhibitor EVP-0334 is pro-cognitive in mice. 38th Annual Meeting for the Society of Neuroscience; 2008; Nov 19; Washington DC. Poster 831.20/I11.
   Google Scholar
• Patzke H, Albayya FP, Bollen E, et al. The novel histone deacetylase inhibitor EVP-0334 is pro-cognitive in rats. 39th Annual Meeting for the Society of Neuroscience; 2009; Oct 21; Chicago, IL. Poster 886.4/FF106.
   Google Scholar
• De Muynck L, Van Damme P. The development of drug therapies for frontotemporal dementia caused by progranulin mutations. In: Atta-ur-Rahman, editor. Frontiers in clinical drug research - Alzheimer disorders. Vol. 3. Sharjah, United Arab Emirates: Bentham Science; 2015. p. 231–291.
   Google Scholar
• Finch N, Baker M, Crook R, et al. Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain. 2009;132:583–591.
   PubMed Web of Science ®Google Scholar
• Sha SJ, Miller ZA, Min SW, et al. An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimers Dement. 2017;3:507–512.
   Google Scholar
• Solfrizzi V, Agosti P, Lozupone M, et al. Nutritional intervention as a preventive approach for cognitive-related outcomes in cognitively healthy older adults: a systematic review. J Alzheimers Dis. 2018;64:S229–S254.
   PubMed Web of Science ®Google Scholar
• Pardini M, Serrati C, Guida S, et al. Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study. Neurodegener Dis. 2015;15:58–62.
   PubMed Web of Science ®Google Scholar
• Merrilees J. A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2007;21:S64–S69.
   PubMed Web of Science ®Google Scholar
• Cheng ST, Chow PK, Song YQ, et al. Mental and physical activities delay cognitive decline in older persons with dementia. Am J Geriatr Psychiatry. 2014;22:63–67.
   PubMed Web of Science ®Google Scholar
• Kortte KB, Rogalski EJ. Behavioural interventions for enhancing life participation in behavioural variant frontotemporal dementia and primary progressive aphasia. Int Rev Psychiatry. 2013;25(2):237–245.
   Web of Science ®Google Scholar
• Tippett DC, Hillis AE, Tsapkini K. Treatment of primary progressive aphasia. Curr Treat Options Neurol. 2015;17:362.
   PubMed Web of Science ®Google Scholar
• Lu CH, Macdonald-Wallis C, Gray E, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247–2257.
   PubMed Web of Science ®Google Scholar
• Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75:116–126.
   PubMed Web of Science ®Google Scholar
• Dani M, Brookes DJ, Edison P. Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2015;16:1139–1150.
   Google Scholar
• Boxer AL, Gold M, Huey E, et al. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013;9:189–198.
   PubMed Web of Science ®Google Scholar
• Semler E, Anderl-Straub S, Uttner I, et al. A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimers Res Ther. 2018;10:41.
   PubMed Web of Science ®Google Scholar